Pparγ1 Facilitates ErbB2-Mammary Adenocarcinoma in Mice

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• HER2 overexpression is common in aggressive breast cancer (BC) and influences treatment response.
• Understanding the genetic drivers of ErbB2-induced tumors is crucial for developing co-extinction therapies.
• Peroxisome proliferator-activated receptor gamma (PPARγ) regulates gene expression in various cancers.

Purpose of the Study:

• To investigate the role of endogenous PPARγ1 in ErbB2-mediated mammary tumor development.
• To identify the genetic programs regulated by PPARγ1 in the context of ErbB2-positive breast cancer.
• To evaluate PPARγ1 as a potential therapeutic target for co-extinction strategies.

Main Methods:

• Genetic deletion of endogenous Pparγ1 in a mouse model.
• Analysis of mammary tumor progression and lipogenesis.
• Assessment of local mammary tumor macrophage infiltration.
• Identification of gene expression modules, including EphA2-Amphiregulin and INFγ/Cxcl5 signaling.
• Chromatin immunoprecipitation to determine PPARγ1 binding targets.

Main Results:

• Genetic deletion of Pparγ1 significantly restrained mammary tumor progression and lipogenesis.
• Pparγ1 deletion induced local mammary tumor macrophage infiltration without affecting hematopoietic stem cells.
• Endogenous Pparγ1 upregulated EphA2-Amphiregulin and INFγ/Cxcl5 signaling pathways, mirroring human breast cancer.
• PPARγ1 directly bound to chromatin of pro-tumorigenic and pro-inflammatory genes.

Conclusions:

• Endogenous Pparγ1 promotes ErbB2-mediated mammary tumor onset and progression.
• PPARγ1 induces expression of EGF-EphA2 receptor tyrosine kinase and cytokine/chemokine modules.
• PPARγ1 drives a pro-tumorigenic inflammatory state, supporting its role as a target for co-extinction therapy in ErbB2 tumors.